SCHEMBL7677909

SCHEMBL7677909

CCCC1C(=O)Oc2c(C)c(C(=O)c3ccccc3)n(C)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 3/20 0.33
HSD17B10 Q99714 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
RECQL P46063 1/20 0.33
GLA P06280 2/20 0.33
CNR2 P34972 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TSHR P16473 1/20 0.32
ABCB11 O95342 1/20 0.32
PTGS2 P35354 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7676758 0.91 NPSR1 (0.40) ALDH1A1LMNAHTTNPSR1KDM4E
SCHEMBL7675526 0.89 ABCB11 (0.42) ALDH1A1HPGDLMNAHTTNPSR1
SCHEMBL7678481 0.82 CYP2C19 (0.41) ALDH1A1HPGDNPSR1KDM4EMAPT
SCHEMBL7677090 0.78 NOD2 (0.34) CNR2
SCHEMBL7674713 0.78 GRM2 (0.39) ALDH1A1HPGDHTTKDM4EHSD17B10
SCHEMBL7680776 0.76 ALDH1A1 (0.39) ALDH1A1HPGDLMNAMAPTHSD17B10
SCHEMBL7682237 0.73 ALDH1A1 (0.40) ALDH1A1HPGDLMNAHTTMAPT
SCHEMBL7678745 0.72 ALDH1A1 (0.36) ALDH1A1HPGDLMNAKDM4EMAPT
SCHEMBL7675544 0.72 MEN1 (0.36) ALDH1A1HPGDLMNAHTTNPSR1
SCHEMBL7675834 0.71 ABCB11 (0.41) ALDH1A1HPGDLMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885HPGD 363/4885LMNA 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.